Nuclear Medicine and Biology
Volume 35, Issue 5 , Pages 523-527 , July 2008

True radiotracers: are we approaching theoretical specific activity with Tc-99m and I-123?

  • William C. Eckelman

      Affiliations

    • Molecular Tracer LLC Bethesda MD 20814
    • Corresponding Author InformationCorresponding author. Molecular Tracer LLC Bethesda MD 20814.
    • ,
  • Mauro Bonardi

      Affiliations

    • Department of Radiology and Radiopharmaceutical Sciences Institute University of Missouri and Research Service H.S. Truman Memorial VA Hospital Columbia, Missouri, 65201, USA
    • ,
  • Wynn A. Volkert

      Affiliations

    • Università degli Study and INFN-Milano, LASA, Radiochemistry Laboratory Via F. 11i Cervi 201, 20090 Segrate, Milano, Italy

References 

  1. Levi H. “George Hevesy and his concept of radioactive indicators—in retrospect”. Eur J Nucl Med Mol Imaging. 1976;1:3–10
  2. Ehrlich P. In: On immunity, with special reference to cell-life (Croonian Lecture, Royal Society of London, 1990), reprinted in Collected Papers of Ehrlich P, vol 2, ed. Himmelweit, New York, NY: Pergamon Press; 1957;p. 178–195
  3. Scheibe PO. Identifiability analysis of second-order systems. Nucl Med Biol. 2003;30(8):827–832
  4. Kilbourn MR. Fluorine-18 labeling of radiopharmaceuticals. In: Prepared for the Committee on Nuclear and Radiochemistry, National Research Council. Washington (DC): National Academy Press; 1990;p. 17–18
  5. Coenen HH, Dutschika K, Muller SP, et al. N.C.A. Radiosynthesis of [123,124I]b-CIT, plasma analysis and pharmacokinetic studies with SPECT and PET. Nucl Med Biol. 1995;22:977–984
  6. Boswell CA, Brechbiel MW. Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view. Nucl Med Biol. 2007;34:757–778
  7. http://www.IUPAC.org, Project of analytical chemistry division: terminology, quantities and units concerning production and applications of radionuclides in radiopharmaceutical and radioanalytical chemistry, Chair Mauro L. Bonardi.
  8. Szajek LP, Kao CHK, Kiesewetter DO, Sassaman MB, Lang L, Plascjak P, et al. Semi-remote production of Br-76 and preparation of high specific activity radiobrominated pharmaceuticals for PET studies. Radiochim Acta. 2004;92:291–295
  9. Laforest R, Rowland DJ, Welch MJ. MicroPET imaging with non-conventional isotopes. Nuclear science symposium conference record. IEEE. 2001;3:1572–1576
  10. Alfassi ZB, Groppi F, Bonardi ML, et al. On the “artificial” nature of Tc and the “carrier-free” nature of 99mTc from 99Mo/99mTc generators. Appl Radiat Isot. 2005;63:37–40
  11. Boyd RE. Technetium-99m generators the available options. Int J Appl Radiat lsot. 1982;33:801–809
  12. Bonardi ML, Birattari C, Groppi F, et al. Cyclotron production and quality control of “high specific activity” radionuclides in “no-carrier-added” form for radioanalytical applications in the life sciences. J Radioanal Nucl Chem. 2004;259(3):415
  13. Bonardi ML, De Goeij JJM, Radioanal J. How do we ascertain specific activities in no-carrier-added radionuclide preparations?. Nucl Chem. 2005;263(1):87
  14. De Goeij JJM, Bonardi ML, Radioanal J. How do we define the concepts specific activity, radioactive concentration, carrier, carrier-free and no-carrier-added?. Nucl Chem. 2005;263(1):13
  15. Srivistava SC, Meinken G, Smith TD, Richards P. Problems associated with stannous 99mTc-radiopharmaceuticals. Appl Radiat Isot. 1977;28:83
  16. Farrington KJ. High pressure liquid chromatography assay of technetium in solutions of sodium pertechnetate produced at the AAEC research establishment. Australian Atomic Energy Commission. 1985;AAEC/E619, ISBN 064259818 5
  17. Bonnyman J. Effect of milking efficiency on 99Tc content of 99mTc generator. Appl Radiat Isot. 1983;34:901
  18. Hill DM, Barnes RK, Wong HKY, Zawadzki AW. The quantification of technetium in generator-derived pertechnetate using ICP-MS. Appl Radiat Isot. 2000;53:415–419
  19. Hou X, Jensen M, Nielsen SP. Use of 99mTc from a commercial 99Mo/99mTc generator as yield tracer for the determination of 99Tc at low levels. Appl Radiat Isot. 2007;65:610–618
  20. Eersels JLH, Travis MJ, Herscheid JDM. Manufacturing I-123-labelled radiopharmaceuticals. Pitfalls and solutions. J Label Compd Radiopharm. 2005;48:241–257
  21. NIST Chemistry WebBook. NIST Standard Reference Database Number 69, June 2005 Release.
  22. Storch D, Behe M, Walter MA, et al. Evaluation of [99mTc/EDDA/HYNICo] octreotide derivatives compared with [111In-DOTAo, Tyr3, Thr8] Octreotide and [111In-DTPAo] octreotide: does tumor or pancreas uptake correlate with the rate of internalization?. J Nucl Med. 2005;46:1561–1569
  23. Smith CJ, Sieckman GL, Owen NK, et al. Radiochemical investigations of gastric releasing peptide receptor-specific [99mTc(X)(CO)3-Dpr-Ser-Ser-Gln-Trp-Ala-Val-Gly-His-Leu-Met-(NH2)] in PC-3, tumor bearing rodent models: synthesis, radiolabeling, and in vitro/in vivo studies where Dpr 2,3-diaminopropionic acid and X=H20) or P(CH2OH)3. Cancer Res. 2003;63:4082–4088
  24. Greenland WE, Howland K, Hardy J, et al. Solid-phase synthesis of peptide radiopharmaceuticals using Fmoc-N-epsilon-(Hynic-Boc)-lysine, a technetium binding amino acid: application to Tc-99m-labeled salmon calcitonin. J Med Chem. 2003;46:1750–1757
  25. Riddoch RW, Schaffer P, Valliant JF. A solid-phase labeling strategy for the preparation of technetium and rhenium bifunctional chelate complexes and associated peptide conjugates. Bioconjug Chem. 2006;17:226–235
  26. Storch D, Schmitt JS, Waldherr C, et al. Preclinical evaluation of somatostatin analogs bearing two macrocyclic chelators for high specific activity labeling with radiometals. Radiochim Acta. 2007;95:359–369
  27. Reubi JC. Peptide receptors in molecular targets for cancer diagnostic and therapy. Endocr Rev. 2003;24:389–427
  28. Cone RD, Lu D, Koppula S, et al. The melanocortin receptors: agonists, antagonists, and the hormonal control of pigmentation. Recent Prog Horm Res. 1996;51:287–317
  29. Chen JC, Cheng Z, Hoffman TJ, et al. Melanoma-targeting properties of 99mTc-labeled cyclic a-melanocyte stimulating hormone peptide analogues. Cancer Res. 2000;60:5649–5658
  30. Virgolini I, Raderer M, Kurtaran A, et al. Vasoactive intestinal peptide-receptor imaging for localization of intestinal adenocarcinomas and endocrine tumors. N Engl J Med. 1994;331:1116–1121
  31. Schaffalitzky DE, Muckadel OB, Aggestrup S, Stentoft P. Flushing and plasma substance P concentration during infusion of synthetic substance P in normal man. Scand J Gastroenterol. 1986;21:498–502
  32. Jansen JB, Jebbink MC, Douglas BR, et al. Effect of loxiglumide (CR-1505) on bombesin- and meal-stimulated plasma cholecystokinin in man. Eur J Clin Pharmacol. 1990;38:367–370
  33. Bertaccini G, Impicciatore M, Molina E, Zappia L. Action of bombesin on human gastrointestinal tract — in vitro. Acta Biomed. 1973;44(3):159–166
  34. Hoffman TJ, Quinn TP, Volkert WA. Radiometalled receptor-avid peptide conjugates for specific in vivo targeting of cancer cells. Nucl Med Biol. 2001;28:527–539
  35. Smith CJ, Gali H, Sieckman GL, et al. Radiochemical investigations of 99mTc-N3S-X-BBN(7-14) NH2; an in vitro/in vivo structure-activity relationships study where X = 0,3,5,8, and 11 carbon tethering modalities. Bioconjug Chem. 2003;14:93–102
  36. Van de Wiele C, Dumont F, VandenBroecke R, et al. Tc-99mRP527, a GRP analogue for visualization of GRP receptor expressing malignancies: a feasibility study. Eur J Nucl Med. 2000;11:1694–1699
  37. Van de Wiele C, Dumont F, Dierckx RA, et al. Biodistribution and dosimetry of Tc-99m-RP527, a gastrin-releasing peptide (GRP) agonist for the visualization of GRP-receptor-expressing malignancies. J Nucl Med. 2001;42:1722–1727
  38. Kuhl DE, Koeppe RA, Fessler JA, Minoshima S, Ackermann RJ, Carey JE, et al. In vivo mapping of cholinergic neurons in the human brain using SPECT and IBVM. J Nucl Med. 1994;35(3):405–410
  39. Ravert HT, Bencherif B, Madar I, Frost JJ. PET imaging of opioid receptors in pain: progress and new directions. Curr Pharm Des. 2004;10(7):759–768
  40. Pimm MV. Circulating antigen: bad or good for immunoscintigraphy?. Nucl Med Biol. 1995;22:137–145
  41. Kobayashi H, Sun BF, Yoo TM, et al. Circulating antigen on biodistribution of 1251 labeled AntiTac dsFv: preinjection of intact antibody versus clearance of antigen with avidin-biotin system. Nucl Med Biol. 1999;40:1381–1391
  42. de Jong M, Breeman WA, Bernard BF, et al. Tumor uptake of the radiolabeled somatostatin analog [DOTAo, Tyr3]octreotide is dependent upon peptide amount. Eur J Nucl Med. 1999;26:693–698
  43. Lantry LE, Cappelletti E, Maddelena ME, et al. 177Lu-AMBA: synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer. J Nucl Med 2006:47:11--44--1152.
  44. Breeman WA, Kwekkeboom DJ, Kooij PP, et al. Effect of dose and specific activity on tissue distribution of indium-111-pentreotide in rats. J Nucl Med. 1995;36:625–627
  45. Kung HF, Kung MP, Wey SP, et al. Clinical acceptance of a molecular imaging agent: a long march with [99mTc]TRODAT. Nucl Med Biol. 2007;34:787–798
  46. Hyllbrant B, Tyrefors N, Markides KE, Langstrom B. On the use of liquid chromatography with radio and ultraviolet absorbance detection coupled to mass spectrometry for improved sensitivity and selectivity in determination of specific radioactivity of radiopharmaceuticals. J Pharm Biomed Anal. 1999;20:493–501
  47. Vuong BK, Kiesewetter DO, Lang L, Ma Y, Eckelman WC, Channing MA. An automated one-step one-pot [(18)F]FCWAY synthesis: development and minimization of chemical impurities. Nucl Med Biol. 2007;34(4):433–438

PII: S0969-8051(08)00075-9

doi: 10.1016/j.nucmedbio.2008.03.005

Nuclear Medicine and Biology
Volume 35, Issue 5 , Pages 523-527 , July 2008

Article Tools